June 10, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 10 June 2019 Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that they have each received a request for additional... Read more

June 6, 2019 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Konica Minolta to Join Global Oncogenic Gene Panel Research

Move Strengthens Konica Minolta’s Advance into Personalized Medicine in Japan with Next-Generation Screening Capabilities Tokyo (June 6, 2019) – Konica Minolta, Inc. (Konica Minolta) today announces agreement with the University of Tokyo (UTokyo) and the National Cancer Center Japan (NCC) to research and develop the next generation Todai OncoPanel (TOP) , a world-leading oncogenic panel test.... Read more

June 6, 2019 Clinical Research/Diagn. M&A, Partnerships

bioMérieux increases its holding in Hybiome from 54% to 67%

06 June, 2019 bioMérieux, a world leader in the field of in vitro diagnostics, today announced an increase of its shareholding in Suzhou Hybiome Biomedical Engineering Co. Ltd. This announcement follows the earlier announcement of the acquisition of a majority stake in this company in November 2018. Founded in 2009 and located in Suzhou (China), Hybiome is specialized... Read more

June 5, 2019 Clinical Research/Diagn. Lab Top-10

Merck KGaA, Darmstadt, Germany, Opens Application Phase for Next Accelerator

05 JUN 2019 | DARMSTADT, GERMANY Start-ups can apply for programs at company headquarters in Darmstadt or in China Focus is on four fields: biosensing & interfaces, liquid biopsy technologies, clean meat, and artificial intelligence (AI)-enabled health solutions Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that that it has opened the next... Read more

June 5, 2019 Clinical Research/Diagn. M&A, Partnerships

QIAGEN and DiaSorin collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease

Germantown, Maryland; Hilden, Germany and Saluggia, Italy, June 5, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the expansion of their QuantiFERON collaboration to develop an ultra-sensitive diagnostic test for Lyme disease, which is expected to address a significant unmet medical need. The companies plan multi-site clinical... Read more

June 4, 2019 Clinical Research/Diagn. M&A, Partnerships

Cofactor Joins FNIH Biomarkers Consortium to Add Predictive Immune Modeling Expertise as New Resource for Multidimensional Biomarker Discovery

— Contributing to both the Cancer and Inflammation and Immunity Steering Committees —SAN FRANCISCO, June. 4, 2019 (BUSINESS WIRE) – Cofactor Genomics, pioneers in the field of Predictive Immune Modeling, announced today that they have become a member of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium with the goal of advancing... Read more

June 4, 2019 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Bio-Techne to Acquire B-MoGen Biotechnologies Inc.

JUNE 04, 2019 MINNEAPOLIS, June 4, 2019 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) announced today it has reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc. The transaction has been completed and is being financed through available cash on hand. “We are very pleased to include the B-MoGen technology in Bio-Techne’s expanding portfolio... Read more

June 4, 2019 Clinical Research/Diagn. Lab Top-10 Life Science Tools Product Launch

Illumina Introduces Expanded Version of VeriSeq™ NIPT Solution, Offering More Comprehensive Detection of Rare Chromosomal Conditions

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced the launch of VeriSeq™ NIPT Solution v2, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). The automated comprehensive solution allows laboratories to screen for a broader range of chromosomal and sub-chromosomal conditions associated with birth defects and adverse pregnancy outcomes than the standard NIPT... Read more

June 4, 2019 Clinical Research/Diagn. Lab Top-10 Product Launch

New Instrument for Automated Antimicrobial Susceptibility Testing Provides Gold Standard-Level Minimum Inhibitory Concentration (MIC) Accuracy1

New Instrument for Automated Antimicrobial Susceptibility Testing Provides Gold Standard-Level Minimum Inhibitory Concentration (MIC) Accuracy1 Instrument utilizes gold standard broth microdilution method to guide more targeted patient therapy and optimize patient outcomes BASINGSTOKE, England. (June 4, 2019) – A new benchtop automated reading and incubation system is now available in Europe for antimicrobial susceptibility testing... Read more

June 4, 2019 Clinical Research/Diagn. Product Launch

New Report Sheds Light on Health Care's 'Hidden' Epidemic – Hospital Drug Diversion – and its Role in the Opioid Crisis

FRANKLIN LAKES, N.J., June 4, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released a new report based on an independent national survey that examines drug diversion in U.S. hospitals, an underreported contributor to the opioid epidemic. Hospital drug diversion, when a health care worker “diverts” opiates... Read more